No Data
Haixin Group Unit Gets Registration, API Approval in China for Intubation Sedative
Shanghai Haixin Group (600851.SH): Chairman Fei Minhua has resigned.
On December 31, Gelonghui reported that Shanghai Haixin Group (600851.SH) announced the receipt of a written resignation report submitted by Mr. Fei Minhua, the company's chairman. Mr. Fei Minhua applied to resign from the positions of director and chairman of the company due to the recommendation of the Shareholder for alternative arrangements for his work; he also resigned as the chairman of the Board of Directors' Global Strategy Committee and as a member of the Board of Directors' Nomination Committee, and will no longer hold any other positions in the company after his resignation.
Earnings Not Telling The Story For Shanghai Haixin Group Co., Ltd. (SHSE:600851) After Shares Rise 26%
Shanghai Haixin Group Co., Ltd.'s (SHSE:600851) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 13% Last Week
Shanghai Haixin Group (600851.SH): The operation scope of Shanghai Haixin Biotechnology Co., Ltd. does not involve AI medicine.
Gelonghui November 22nd | Shanghai haixin group (600851.SH) stated on the investor interaction platform that shanghai haixin biotechnology co., ltd. does not involve AI medicine in its operation scope.
Earnings Are Growing at Shanghai Haixin Group (SHSE:600851) but Shareholders Still Don't Like Its Prospects
Shanghai Haixin Group Co., Ltd.'s (SHSE:600851) Share Price Not Quite Adding Up
